You searched for "MDT"

113 results found

MDT meetings in urogynaecology

This study aimed to assess the outcome of case discussion at a single unit’s urogynaecology multidisciplinary team (MDT) meetings. This was a retrospective study of the MDT proformas of 106 patients who were discussed over a 14-month period. Various outcomes...

Urology MDTs: what members think

This study aimed to examine the functionality of urology cancer multidisciplinary team meetings (MDTs). Evidence has suggested that urology MDTs are not as well structured as other surgical disciplines. MDT members were asked their views on if there were any...

The multidisciplinary team meeting: London calling!

The multidisciplinary team meeting, or MDT, is the foundation of cancer management in the UK. The MDT consists of a group of experts in different fields of medicine and surgery coming together at regular intervals to discuss the diagnosis and...

The Management of Small Renal Masses

I enjoyed reading this book and was surprised at how much practically useful information was contained within such a slim volume. The 171-page volume was easy to read in its entirety in a short space of time. It’s small enough...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...

Mesh in urological surgery in the UK – background, reviews and current status

All UK urologists, unless they have been on a 10-year silent retreat, are by now aware of the controversy surrounding surgical use of mesh in general and urological / urogynaecological use of mesh for the surgical treatment of stress urinary...

Abiraterone acetate in men with castration-resistant prostate cancer

With emerging results from the Stampede and Latitude studies, abiraterone has taken the forefront in the management of metastatic prostate cancer while researchers try to identify the ideal timing for administration. It is a potent inhibitor of CYP17 which results...

Technology for remote working and COVID-19 resources

The COVID-19 pandemic has altered every aspect of how we live, and how healthcare needs to be provided for the welfare of patients and staff. I thought I would try to summarise a few potential technology tools that could be...

Urological Cancer Management

This was all in all a pretty good read. It covers a wide range of topics authoritatively and with a degree of confidence that allows for quite a focused discussion on a range of malignancies from adrenal glands to penile...

Oncological Imaging: Urology

Imaging updates on renal tumours, urothelial tumours, prostate, adrenal and retroperitoneal tumours are all covered in this text. Whilst aspects relating to prostate imaging are probably covered better elsewhere, what remains is a decent account nicely contained within a single...

Advanced prostate cancer and chemotherapy

The treatment pathway for advanced prostate cancer is both puzzling and complex and varies from centre to centre in the UK. The National Prostate Cancer Audit Report 2019 for England and Wales shows that only a quarter of men with...

Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility study

Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...